+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Anticoagulants Market by Drug Class, Route Of Administration, Indication, End User, Distribution Channel, Dosage Form - Global Forecast to 2030- Product Image
Anticoagulants Market by Drug Class, Route Of Administration, Indication, End User, Distribution Channel, Dosage Form - Global Forecast to 2030- Product Image
Sale

Anticoagulants Market by Drug Class, Route Of Administration, Indication, End User, Distribution Channel, Dosage Form - Global Forecast to 2030

  • PDF Icon

    Report

  • 197 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 4904671
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Anticoagulants Market is experiencing robust growth, transitioning from a value of USD 44.24 billion in 2024 to an anticipated USD 48.92 billion in 2025, with projections to reach USD 79.15 billion by 2030 at a CAGR of 10.18%.

Introducing the Future of Anticoagulant Therapies

This report delves into the dynamic landscape of anticoagulant therapies, spotlighting burgeoning innovations that are redefining clinical approaches. With rising thrombotic disorder incidences and expanding patient demographics, the sector is driven by the need for finer therapeutic precision. Emerging molecules and novel delivery systems are creating waves, prompting industry players to revitalize research initiatives.

The seamless integration of clinical evidence with technological advancements has notably spurred direct oral anticoagulants' introduction, significantly reshaping patient adherence and prescribing trends. This evolution provides strategic insights into market drivers, regulatory contexts, and patient needs, essential for capitalizing on growth trajectories.

Pivotal Shifts Redefining the Anticoagulant Ecosystem

Anticoagulant development is no longer about incremental improvements but transformative shifts. The switch from injectable heparins to oral formulations underpins these changes, enhancing patient convenience while easing healthcare burdens. Drug classes have evolved into distinct thrombin and factor Xa inhibitors, refining therapeutic decisions based on individual risk profiles.

Pharmacogenomics and biomarker-driven care are enhancing personalization, reducing adverse events, and optimizing outcomes. Digital health tools further revolutionize patient engagement and adherence, contributing to improved therapeutic efficacy.

Assessing the Ripple Effects of US Tariffs in 2025

The imposition of US tariffs in 2025 has complicated the global market, affecting cost structures and supply chains. Manufacturers face cost escalations and are exploring alternative procurement and long-term contract strategies to maintain stability. Regional distribution has adapted with diversified manufacturing and strategic partnerships to mitigate tariff impacts, reinforcing supply chain resilience.

Healthcare providers are closely monitoring these developments, and some shifts toward cost-effective alternatives are evident, challenging established brands to prove their clinical and economic advantages.

Key Takeaways from This Report

  • Strategic insights into new therapeutic developments and market drivers demonstrate a comprehensive overview of the evolving landscape.
  • In-depth segmentation analysis provides clarity on product positioning and market dynamics, aiding in strategic planning and competitive differentiation.
  • Critical regional assessments highlight differing adoption and reimbursement patterns, offering a blueprint for tailored market access and entry strategies.

Unveiling Critical Market Segmentation Drivers

Understanding market segmentation is crucial for identifying growth avenues. The market is diverse, encompassing direct oral anticoagulants, traditional agents like low molecular weight heparins, and Vitamin K antagonists. This segmentation framework informs strategies across drug development, marketing, and medical affairs, aligning with distinct market needs.

Segmentation extends into administration routes, indications, and end-users, emphasizing clinical and operational characteristics that define market dynamics and opportunities.

Decoding Regional Variations in Market Dynamics

Regional dynamics play a pivotal role, influenced by healthcare infrastructures and regulatory environments. For instance, the Americas benefit from strong cardiovascular research investments, while Europe and the Middle East showcase a mix of harmonized regulations and localized decisions.

Meanwhile, Asia-Pacific presents high-growth potential with diverse regulatory landscapes, underscoring the necessity of strategic market access plans to leverage region-specific opportunities.

Spotlight on Leading Industry Players

Top pharmaceutical and biotech companies are reshaping this landscape with innovative pipelines and strategic alliances. Multinational giants focus on next-gen inhibitors, while niche innovators explore unique delivery systems, exemplifying agility and collaborative opportunities.

Partnerships are increasingly focusing on digital therapeutics and pharmacogenomic advancements to foster comprehensive solutions extending beyond traditional therapies.

Strategic Imperatives for Market Leadership

Success in the anticoagulant market hinges on strategic adaptability and patient-centric innovation. Emphasizing precision medicine, engaging in early payer dialogues, and building cross-sector partnerships are crucial for sustaining growth and competitive positioning.

Robust supply chain strategies and data-driven decision-making are imperative to mitigate risks and support uninterrupted product availability, ensuring sustained market leadership.

Robust Framework Underpinning the Analysis

This report is founded on a meticulous research methodology, incorporating primary and secondary data sources. Rigorous interviews and comprehensive data triangulation ensure reliable insights and actionable recommendations.

Extensive coverage of product pipelines, competitive dynamics, and robust segmentation schemas provides stakeholders with a reliable foundation for informed strategic decisions in anticoagulant therapies.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Anticoagulants Market, by Drug Class
8.1. Introduction
8.2. Direct Oral Anticoagulants
8.2.1. Direct Thrombin Inhibitors
8.2.1.1. Dabigatran
8.2.2. Factor Xa Inhibitors
8.2.2.1. Apixaban
8.2.2.2. Betrixaban
8.2.2.3. Edoxaban
8.2.2.4. Rivaroxaban
8.3. Low Molecular Weight Heparin
8.3.1. Dalteparin
8.3.2. Enoxaparin
8.3.3. Tinzaparin
8.4. Unfractionated Heparin
8.5. Vitamin K Antagonists
8.5.1. Phenprocoumon
8.5.2. Warfarin
9. Anticoagulants Market, by Route Of Administration
9.1. Introduction
9.2. Injectable
9.2.1. Intravenous
9.2.2. Subcutaneous
9.3. Oral
10. Anticoagulants Market, by Indication
10.1. Introduction
10.2. Atrial Fibrillation
10.3. Deep Vein Thrombosis
10.4. Pulmonary Embolism
10.5. Venous Thromboembolism Prevention
11. Anticoagulants Market, by End User
11.1. Introduction
11.2. Ambulatory Surgical Centers
11.3. Clinics
11.4. Homecare Settings
11.5. Hospitals
12. Anticoagulants Market, by Distribution Channel
12.1. Introduction
12.2. Hospital Pharmacy
12.3. Online Pharmacy
12.4. Retail Pharmacy
13. Anticoagulants Market, by Dosage Form
13.1. Introduction
13.2. Prefilled Syringes
13.3. Tablets
13.4. Vials
14. Americas Anticoagulants Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Anticoagulants Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Anticoagulants Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Bristol-Myers Squibb Company
17.3.2. Pfizer Inc.
17.3.3. Bayer Aktiengesellschaft
17.3.4. Johnson & Johnson
17.3.5. Boehringer Ingelheim International GmbH
17.3.6. Daiichi Sankyo Company, Limited
17.3.7. Sanofi S.A.
17.3.8. GlaxoSmithKline plc
17.3.9. Viatris Inc.
17.3.10. Teva Pharmaceutical Industries Limited
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. ANTICOAGULANTS MARKET MULTI-CURRENCY
FIGURE 2. ANTICOAGULANTS MARKET MULTI-LANGUAGE
FIGURE 3. ANTICOAGULANTS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL ANTICOAGULANTS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL ANTICOAGULANTS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL ANTICOAGULANTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 8. GLOBAL ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL ANTICOAGULANTS MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL ANTICOAGULANTS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL ANTICOAGULANTS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL ANTICOAGULANTS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL ANTICOAGULANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 16. GLOBAL ANTICOAGULANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL ANTICOAGULANTS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2030 (%)
FIGURE 18. GLOBAL ANTICOAGULANTS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS ANTICOAGULANTS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS ANTICOAGULANTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES ANTICOAGULANTS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES ANTICOAGULANTS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA ANTICOAGULANTS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA ANTICOAGULANTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ASIA-PACIFIC ANTICOAGULANTS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. ASIA-PACIFIC ANTICOAGULANTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. ANTICOAGULANTS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. ANTICOAGULANTS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. ANTICOAGULANTS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL ANTICOAGULANTS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL ANTICOAGULANTS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL ANTICOAGULANTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL ANTICOAGULANTS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL ANTICOAGULANTS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL ANTICOAGULANTS MARKET SIZE, BY DABIGATRAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL ANTICOAGULANTS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL ANTICOAGULANTS MARKET SIZE, BY FACTOR XA INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL ANTICOAGULANTS MARKET SIZE, BY APIXABAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL ANTICOAGULANTS MARKET SIZE, BY BETRIXABAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL ANTICOAGULANTS MARKET SIZE, BY EDOXABAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL ANTICOAGULANTS MARKET SIZE, BY RIVAROXABAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL ANTICOAGULANTS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL ANTICOAGULANTS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL ANTICOAGULANTS MARKET SIZE, BY LOW MOLECULAR WEIGHT HEPARIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL ANTICOAGULANTS MARKET SIZE, BY DALTEPARIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL ANTICOAGULANTS MARKET SIZE, BY ENOXAPARIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL ANTICOAGULANTS MARKET SIZE, BY TINZAPARIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL ANTICOAGULANTS MARKET SIZE, BY LOW MOLECULAR WEIGHT HEPARIN, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL ANTICOAGULANTS MARKET SIZE, BY UNFRACTIONATED HEPARIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL ANTICOAGULANTS MARKET SIZE, BY VITAMIN K ANTAGONISTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL ANTICOAGULANTS MARKET SIZE, BY PHENPROCOUMON, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL ANTICOAGULANTS MARKET SIZE, BY WARFARIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL ANTICOAGULANTS MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL ANTICOAGULANTS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL ANTICOAGULANTS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL ANTICOAGULANTS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL ANTICOAGULANTS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL ANTICOAGULANTS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL ANTICOAGULANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL ANTICOAGULANTS MARKET SIZE, BY ATRIAL FIBRILLATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL ANTICOAGULANTS MARKET SIZE, BY DEEP VEIN THROMBOSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL ANTICOAGULANTS MARKET SIZE, BY PULMONARY EMBOLISM, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL ANTICOAGULANTS MARKET SIZE, BY VENOUS THROMBOEMBOLISM PREVENTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL ANTICOAGULANTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL ANTICOAGULANTS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL ANTICOAGULANTS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL ANTICOAGULANTS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL ANTICOAGULANTS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL ANTICOAGULANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL ANTICOAGULANTS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL ANTICOAGULANTS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL ANTICOAGULANTS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL ANTICOAGULANTS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL ANTICOAGULANTS MARKET SIZE, BY PREFILLED SYRINGES, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL ANTICOAGULANTS MARKET SIZE, BY TABLETS, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL ANTICOAGULANTS MARKET SIZE, BY VIALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS ANTICOAGULANTS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS ANTICOAGULANTS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS ANTICOAGULANTS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 56. AMERICAS ANTICOAGULANTS MARKET SIZE, BY LOW MOLECULAR WEIGHT HEPARIN, 2018-2030 (USD MILLION)
TABLE 57. AMERICAS ANTICOAGULANTS MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 58. AMERICAS ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 59. AMERICAS ANTICOAGULANTS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 60. AMERICAS ANTICOAGULANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 61. AMERICAS ANTICOAGULANTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 62. AMERICAS ANTICOAGULANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 63. AMERICAS ANTICOAGULANTS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 64. AMERICAS ANTICOAGULANTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 65. UNITED STATES ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 66. UNITED STATES ANTICOAGULANTS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 67. UNITED STATES ANTICOAGULANTS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 68. UNITED STATES ANTICOAGULANTS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 69. UNITED STATES ANTICOAGULANTS MARKET SIZE, BY LOW MOLECULAR WEIGHT HEPARIN, 2018-2030 (USD MILLION)
TABLE 70. UNITED STATES ANTICOAGULANTS MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 71. UNITED STATES ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 72. UNITED STATES ANTICOAGULANTS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 73. UNITED STATES ANTICOAGULANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 74. UNITED STATES ANTICOAGULANTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 75. UNITED STATES ANTICOAGULANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 76. UNITED STATES ANTICOAGULANTS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 77. UNITED STATES ANTICOAGULANTS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 78. CANADA ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 79. CANADA ANTICOAGULANTS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 80. CANADA ANTICOAGULANTS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 81. CANADA ANTICOAGULANTS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 82. CANADA ANTICOAGULANTS MARKET SIZE, BY LOW MOLECULAR WEIGHT HEPARIN, 2018-2030 (USD MILLION)
TABLE 83. CANADA ANTICOAGULANTS MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 84. CANADA ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 85. CANADA ANTICOAGULANTS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 86. CANADA ANTICOAGULANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 87. CANADA ANTICOAGULANTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 88. CANADA ANTICOAGULANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 89. CANADA ANTICOAGULANTS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 90. MEXICO ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 91. MEXICO ANTICOAGULANTS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 92. MEXICO ANTICOAGULANTS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 93. MEXICO ANTICOAGULANTS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 94. MEXICO ANTICOAGULANTS MARKET SIZE, BY LOW MOLECULAR WEIGHT HEPARIN, 2018-2030 (USD MILLION)
TABLE 95. MEXICO ANTICOAGULANTS MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 96. MEXICO ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 97. MEXICO ANTICOAGULANTS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 98. MEXICO ANTICOAGULANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 99. MEXICO ANTICOAGULANTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 100. MEXICO ANTICOAGULANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 101. MEXICO ANTICOAGULANTS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 102. BRAZIL ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 103. BRAZIL ANTICOAGULANTS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 104. BRAZIL ANTICOAGULANTS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 105. BRAZIL ANTICOAGULANTS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 106. BRAZIL ANTICOAGULANTS MARKET SIZE, BY LOW MOLECULAR WEIGHT HEPARIN, 2018-2030 (USD MILLION)
TABLE 107. BRAZIL ANTICOAGULANTS MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 108. BRAZIL ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 109. BRAZIL ANTICOAGULANTS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 110. BRAZIL ANTICOAGULANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 111. BRAZIL ANTICOAGULANTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 112. BRAZIL ANTICOAGULANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 113. BRAZIL ANTICOAGULANTS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 114. ARGENTINA ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 115. ARGENTINA ANTICOAGULANTS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 116. ARGENTINA ANTICOAGULANTS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 117. ARGENTINA ANTICOAGULANTS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 118. ARGENTINA ANTICOAGULANTS MARKET SIZE, BY LOW MOLECULAR WEIGHT HEPARIN, 2018-2030 (USD MILLION)
TABLE 119. ARGENTINA ANTICOAGULANTS MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 120. ARGENTINA ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 121. ARGENTINA ANTICOAGULANTS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 122. ARGENTINA ANTICOAGULANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 123. ARGENTINA ANTICOAGULANTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 124. ARGENTINA ANTICOAGULANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 125. ARGENTINA ANTICOAGULANTS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 126. EUROPE, MIDDLE EAST & AFRICA ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 127. EUROPE, MIDDLE EAST & AFRICA ANTICOAGULANTS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 128. EUROPE, MIDDLE EAST & AFRICA ANTICOAGULANTS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 129. EUROPE, MIDDLE EAST & AFRICA ANTICOAGULANTS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 130. EUROPE, MIDDLE EAST & AFRICA ANTICOAGULANTS MARKET SIZE, BY LOW MOLECULAR WEIGHT HEPARIN, 2018-2030 (USD MILLION)
TABLE 131. EUROPE, MIDDLE EAST & AFRICA ANTICOAGULANTS MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 132. EUROPE, MIDDLE EAST & AFRICA ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 133. EUROPE, MIDDLE EAST & AFRICA ANTICOAGULANTS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 134. EUROPE, MIDDLE EAST & AFRICA ANTICOAGULANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 135. EUROPE, MIDDLE EAST & AFRICA ANTICOAGULANTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 136. EUROPE, MIDDLE EAST & AFRICA ANTICOAGULANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 137. EUROPE, MIDDLE EAST & AFRICA ANTICOAGULANTS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 138. EUROPE, MIDDLE EAST & AFRICA ANTICOAGULANTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 139. UNITED KINGDOM ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 140. UNITED KINGDOM ANTICOAGULANTS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 141. UNITED KINGDOM ANTICOAGULANTS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 142. UNITED KINGDOM ANTICOAGULANTS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 143. UNITED KINGDOM ANTICOAGULANTS MARKET SIZE, BY LOW MOLECULAR WEIGHT HEPARIN, 2018-2030 (USD MILLION)
TABLE 144. UNITED KINGDOM ANTICOAGULANTS MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 145. UNITED KINGDOM ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 146. UNITED KINGDOM ANTICOAGULANTS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 147. UNITED KINGDOM ANTICOAGULANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 148. UNITED KINGDOM ANTICOAGULANTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 149. UNITED KINGDOM ANTICOAGULANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 150. UNITED KINGDOM ANTICOAGULANTS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 151. GERMANY ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 152. GERMANY ANTICOAGULANTS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 153. GERMANY ANTICOAGULANTS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 154. GERMANY ANTICOAGULANTS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 155. GERMANY ANTICOAGULANTS MARKET SIZE, BY LOW MOLECULAR WEIGHT HEPARIN, 2018-2030 (USD MILLION)
TABLE 156. GERMANY ANTICOAGULANTS MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 157. GERMANY ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 158. GERMANY ANTICOAGULANTS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 159. GERMANY ANTICOAGULANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 160. GERMANY ANTICOAGULANTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 161. GERMANY ANTICOAGULANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 162. GERMANY ANTICOAGULANTS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 163. FRANCE ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 164. FRANCE ANTICOAGULANTS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 165. FRANCE ANTICOAGULANTS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 166. FRANCE ANTICOAGULANTS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 167. FRANCE ANTICOAGULANTS MARKET SIZE, BY LOW MOLECULAR WEIGHT HEPARIN, 2018-2030 (USD MILLION)
TABLE 168. FRANCE ANTICOAGULANTS MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 169. FRANCE ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 170. FRANCE ANTICOAGULANTS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 171. FRANCE ANTICOAGULANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 172. FRANCE ANTICOAGULANTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 173. FRANCE ANTICOAGULANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 174. FRANCE ANTICOAGULANTS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 175. RUSSIA ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 176. RUSSIA ANTICOAGULANTS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 177. RUSSIA ANTICOAGULANTS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 178. RUSSIA ANTICOAGULANTS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 179. RUSSIA ANTICOAGULANTS MARKET SIZE, BY LOW MOLECULAR WEIGHT HEPARIN, 2018-2030 (USD MILLION)
TABLE 180. RUSSIA ANTICOAGULANTS MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 181. RUSSIA ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 182. RUSSIA ANTICOAGULANTS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 183. RUSSIA ANTICOAGULANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 184. RUSSIA ANTICOAGULANTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 185. RUSSIA ANTICOAGULANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 186. RUSSIA ANTICOAGULANTS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 187. ITALY ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 188. ITALY ANTICOAGULANTS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 189. ITALY ANTICOAGULANTS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 190. ITALY ANTICOAGULANTS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 191. ITALY ANTICOAGULANTS MARKET SIZE, BY LOW MOLECULAR WEIGHT HEPARIN, 2018-2030 (USD MILLION)
TABLE 192. ITALY ANTICOAGULANTS MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 193. ITALY ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 194. ITALY ANTICOAGULANTS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 195. ITALY ANTICOAGULANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 196. ITALY ANTICOAGULANTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 197. ITALY ANTICOAGULANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 198. ITALY ANTICOAGULANTS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 199. SPAIN ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 200. SPAIN ANTICOAGULANTS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 201. SPAIN ANTICOAGULANTS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 202. SPAIN ANTICOAGULANTS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 203. SPAIN ANTICOAGULANTS MARKET SIZE, BY LOW MOLECULAR WEIGHT HEPARIN, 2018-2030 (USD MILLION)
TABLE 204. SPAIN ANTICOAGULANTS MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 205. SPAIN ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 206. SPAIN ANTICOAGULANTS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 207. SPAIN ANTICOAGULANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 208. SPAIN ANTICOAGULANTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 209. SPAIN ANTICOAGULANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 210. SPAIN ANTICOAGULANTS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 211. UNITED ARAB EMIRATES ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 212. UNITED ARAB EMIRATES ANTICOAGULANTS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 213. UNITED ARAB EMIRATES ANTICOAGULANTS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 214. UNITED ARAB EMIRATES ANTICOAGULANTS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 215. UNITED ARAB EMIRATES ANTICOAGULANTS MARKET SIZE, BY LOW MOLECULAR WEIGHT HEPARIN, 2018-2030 (USD MILLION)
TABLE 216. UNITED ARAB EMIRATES ANTICOAGULANTS MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 217. UNITED ARAB EMIRATES ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 218. UNITED ARAB EMIRATES ANTICOAGULANTS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 219. UNITED ARAB EMIRATES ANTICOAGULANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 220. UNITED ARAB EMIRATES ANTICOAGULANTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 221. UNITED ARAB EMIRATES ANTICOAGULANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 222. UNITED ARAB EMIRATES ANTICOAGULANTS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 223. SAUDI ARABIA ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 224. SAUDI ARABIA ANTICOAGULANTS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 225. SAUDI ARABIA ANTICOAGULANTS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 226. SAUDI ARABIA ANTICOAGULANTS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 227. SAUDI ARABIA ANTICOAGULANTS MARKET SIZE, BY LOW MOLECULAR WEIGHT HEPARIN, 2018-2030 (USD MILLION)
TABLE 228. SAUDI ARABIA ANTICOAGULANTS MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 229. SAUDI ARABIA ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 230. SAUDI ARABIA ANTICOAGULANTS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 231. SAUDI ARABIA ANTICOAGULANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 232. SAUDI ARABIA ANTICOAGULANTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 233. SAUDI ARABIA ANTICOAGULANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 234. SAUDI ARABIA ANTICOAGULANTS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 235. SOUTH AFRICA ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 236. SOUTH AFRICA ANTICOAGULANTS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 237. SOUTH AFRICA ANTICOAGULANTS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 238. SOUTH AFRICA ANTICOAGULANTS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 239. SOUTH AFRICA ANTICOAGULANTS MARKET SIZE, BY LOW MOLECULAR WEIGHT HEPARIN, 2018-2030 (USD MILLION)
TABLE 240. SOUTH AFRICA ANTICOAGULANTS MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 241. SOUTH AFRICA ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 242. SOUTH AFRICA ANTICOAGULANTS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 243. SOUTH AFRICA ANTICOAGULANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 244. SOUTH AFRICA ANTICOAGULANTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 245. SOUTH AFRICA ANTICOAGULANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 246. SOUTH AFRICA ANTICOAGULANTS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 247. DENMARK ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 248. DENMARK ANTICOAGULANTS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 249. DENMARK ANTICOAGULANTS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 250. DENMARK ANTICOAGULANTS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 251. DENMARK ANTICOAGULANTS MARKET SIZE, BY LOW MOLECULAR WEIGHT HEPARIN, 2018-2030 (USD MILLION)
TABLE 252. DENMARK ANTICOAGULANTS MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 253. DENMARK ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 254. DENMARK ANTICOAGULANTS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 255. DENMARK ANTICOAGULANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 256. DENMARK ANTICOAGULANTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 257. DENMARK ANTICOAGULANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 258. DENMARK ANTICOAGULANTS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 259. NETHERLANDS ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 260. NETHERLANDS ANTICOAGULANTS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 261. NETHERLANDS ANTICOAGULANTS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 262. NETHERLANDS ANTICOAGULANTS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 263. NETHERLANDS ANTICOAGULANTS MARKET SIZE, BY LOW MOLECULAR WEIGHT HEPARIN, 2018-2030 (USD MILLION)
TABLE 264. NETHERLANDS ANTICOAGULANTS MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 265. NETHERLANDS ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 266. NETHERLANDS ANTICOAGULANTS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 267. NETHERLANDS ANTICOAGULANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 268. NETHERLANDS ANTICOAGULANTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 269. NETHERLANDS ANTICOAGULANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 270. NETHERLANDS ANTICOAGULANTS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 271. QATAR ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 272. QATAR ANTICOAGULANTS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 273. QATAR ANTICOAGULANTS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 274. QATAR ANTICOAGULANTS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 275. QATAR ANTICOAGULANTS MARKET SIZE, BY LOW MOLECULAR WEIGHT HEPARIN, 2018-2030 (USD MILLION)
TABLE 276. QATAR ANTICOAGULANTS MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 277. QATAR ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 278. QATAR ANTICOAGULANTS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 279. QATAR ANTICOAGULANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 280. QATAR ANTICOAGULANTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 281. QATAR ANTICOAGULANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 282. QATAR ANTICOAGULANTS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 283. FINLAND ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 284. FINLAND ANTICOAGULANTS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 285. FINLAND ANTICOAGULANTS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 286. FINLAND ANTICOAGULANTS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 287. FINLAND ANTICOAGULANTS MARKET SIZE, BY LOW MOLECULAR WEIGHT HEPARIN, 2018-2030 (USD MILLION)
TABLE 288. FINLAND ANTICOAGULANTS MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 289. FINLAND ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 290. FINLAND ANTICOAGULANTS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 291. FINLAND ANTICOAGULANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 292. FINLAND ANTICOAGULANTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 293. FINLAND ANTICOAGULANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 294. FINLAND ANTICOAGULANTS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 295. SWEDEN ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 296. SWEDEN ANTICOAGULANTS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 297. SWEDEN ANTICOAGULANTS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 298. SWEDEN ANTICOAGULANTS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 299. SWEDEN ANTICOAGULANTS MARKET SIZE, BY LOW MOLECULAR WEIGHT HEPARIN, 2018-2030 (USD MILLION)
TABLE 300. SWEDEN ANTICOAGULANTS MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 301. SWEDEN ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 302. SWEDEN ANTICOAGULANTS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 303. SWEDEN ANTICOAGULANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 304. SWEDEN ANTICOAGULANTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 305. SWEDEN ANTICOAGULANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 306. SWEDEN ANTICOAGULANTS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 307. NIGERIA ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 308. NIGERIA ANTICOAGULANTS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 309. NIGERIA ANTICOAGULANTS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 310. NIGERIA ANTICOAGULANTS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 311. NIGERIA ANTICOAGULANTS MARKET SIZE, BY LOW MOLECULAR WEIGHT HEPARIN, 2018-2030 (USD MILLION)
TABLE 312. NIGERIA ANTICOAGULANTS MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 313. NIGERIA ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 314. NIGERIA ANTICOAGULANTS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 315. NIGERIA ANTICOAGULANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 316. NIGERIA ANTICOAGULANTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 317. NIGERIA ANTICOAGULANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 318. NIGERIA ANTICOAGULANTS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 319. EGYPT ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 320. EGYPT ANTICOAGULANTS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 321. EGYPT ANTICOAGULANTS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 322. EGYPT ANTICOAGULANTS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 323. EGYPT ANTICOAGULANTS MARKET SIZE, BY LOW MOLECULAR WEIGHT HEPARIN, 2018-2030 (USD MILLION)
TABLE 324. EGYPT ANTICOAGULANTS MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 325. EGYPT ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 326. EGYPT ANTICOAGULANTS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 327. EGYPT ANTICOAGULANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 328. EGYPT ANTICOAGULANTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 329. EGYPT ANTICOAGULANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 330. EGYPT ANTICOAGULANTS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 331. TURKEY ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 332. TURKEY ANTICOAGULANTS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2018-2030 (USD MILLION)
TABLE 333. TURKEY ANTICOAGULANTS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2030 (USD MILLION)
TABLE 334. TURKEY ANTICOAGULANTS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2030 (USD MILLION)
TABLE 335. TURKEY ANTICOAGULANTS MARKET SIZE, BY LOW MOLECULAR WEIGHT HEPARIN, 2018-2030 (USD MILLION)
TABLE 336. TURKEY ANTICOAGULANTS MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2030 (USD MILLION)
TABLE 337. TURKEY ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 338. TURKEY ANTICOAGULANTS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 339. TURKEY ANTICOAGULANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 340. TURKEY ANTICOAGULANTS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 341. TURKEY ANTICOAGULANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 342. TURKEY ANTICOAGULANTS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 343. ISRAEL ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 344. ISRAEL ANTICOAGULANTS MAR

Companies Mentioned

The companies profiled in this Anticoagulants market report include:
  • Bristol-Myers Squibb Company
  • Pfizer Inc.
  • Bayer Aktiengesellschaft
  • Johnson & Johnson
  • Boehringer Ingelheim International GmbH
  • Daiichi Sankyo Company, Limited
  • Sanofi S.A.
  • GlaxoSmithKline plc
  • Viatris Inc.
  • Teva Pharmaceutical Industries Limited

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages197
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 48.92 Billion
Forecasted Market Value ( USD ) by 2030 $ 79.15 Billion
Compound Annual Growth Rate10.1%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Thrombosis Drug Market by Route of Administration, End User, Treatment Type, Drug Class, Indication - Global Forecast to 2030 - Product Image

Thrombosis Drug Market by Route of Administration, End User, Treatment Type, Drug Class, Indication - Global Forecast to 2030

  • Report
  • 188 Pages
  • Global
From
Anticoagulants Market Size, Share & Trends Analysis Report by Drug Category (Novel Oral Anticoagulants, Direct Thrombin Inhibitors, Heparin), Route of Administration, Application, Region, with Growth Forecasts, 2025-2030 - Product Image

Anticoagulants Market Size, Share & Trends Analysis Report by Drug Category (Novel Oral Anticoagulants, Direct Thrombin Inhibitors, Heparin), Route of Administration, Application, Region, with Growth Forecasts, 2025-2030

  • Report
  • 125 Pages
  • Global
From
Acute Coronary Syndrome Market by Type, Therapeutic Class, End User, Distribution Channel, Route Of Administration - Global Forecast to 2030 - Product Image

Acute Coronary Syndrome Market by Type, Therapeutic Class, End User, Distribution Channel, Route Of Administration - Global Forecast to 2030

  • Report
  • 189 Pages
  • Global
From
Anticoagulants Market 2024-2028 - Product Image

Anticoagulants Market 2024-2028

  • Report
  • 177 Pages
  • Global
From
Anticoagulants Market Report 2025 - Product Image

Anticoagulants Market Report 2025

  • Report
  • 200 Pages
  • Global
From

About the Anticoagulant Market

The anticoagulant market within the context of cardiovascular drugs is a rapidly growing sector of the pharmaceutical industry. Anticoagulants are drugs used to prevent the formation of blood clots, which can lead to serious medical conditions such as stroke and heart attack. These drugs are used to reduce the risk of thrombosis, a condition in which a blood clot forms in a blood vessel, blocking the flow of blood. Anticoagulants are also used to treat existing blood clots, as well as to prevent the formation of new ones. The anticoagulant market is driven by the increasing prevalence of cardiovascular diseases, such as coronary artery disease, stroke, and peripheral artery disease. The rising demand for anticoagulants is also driven by the increasing aging population, as well as the increasing awareness of the importance of preventive healthcare. Some of the major companies in the anticoagulant market include Bayer AG, Bristol-Myers Squibb, Pfizer, Sanofi, and Johnson & Johnson. These companies are engaged in the development, manufacture, and marketing of anticoagulant drugs. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.